clinical trial · NCT07309822
Study to Assess the Safety and Effectiveness of Beltaven® in Patients With Allergy to Apis Mellifera, Polistes Dominula or Vespula Spp.
Probelte Pharma S.L.U.·—·recruiting·n = 27
Allergy
brief summary
Non-interventional Study to Assess the Safety and Effectiveness Profile of a SCIT Therapy With Beltaven® With Apis mellifera, Polistes dominula or Vespula spp. allergic patients
started
Feb 1, 2025
primary completion
May 1, 2031
completion
Dec 1, 2031
last updated
Dec 30, 2025
detailed description
This prospective open multi-centre non-interventional study assess the safety and effectiveness profile of the subcutaneous allergen-specific immunotherapy with Beltaven in Apis mellifera, Polistes dominula or Vespula spp (children and adults) in routine medical care.
official title
Observational Prospective Study to Assess the Safety and Effectiveness of Beltaven® in Patients With Allergy to Apis Mellifera, Polistes Dominula or Vespula Spp
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol